http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022065863-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1ca2fe5a1e9022aa0323cbb48d30f5e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2570-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-103 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 |
| filingDate | 2021-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9331bf8456bd02f2ca009b87ecd32067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0258f45075566560e974c65963937990 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bd328c79ed05d675e41a70493559c20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274c62d846aaa281d6c47b927f251a35 |
| publicationDate | 2022-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022065863-A1 |
| titleOfInvention | Predictive biomarkers for adverse effects of radiation therapy |
| abstract | Methods of treating with radiation therapy a subject having cancer, in which the method comprises administering radiation therapy to the subject. The subject does not have an increased risk of having an adverse reaction to radiation therapy. The subject has an increased risk of an adverse reaction to radiation therapy when the subject's level of each component in a component profile from a sample of the subject is altered as compared to the normal level of each component. The component profile may comprise a metabolite panel of geranyl pyrophosphate, glucose-1-phosphate, and 3-hydroxy-3-methylglutaryl-CoA; a lipid panel of LPA 18:0, LPA 16:0, LPC 20:2, CER 24:0, and LPI 16:1; or a combination of these panels. The component profile may also comprise a metabolite panel of metanephrine, tryptophan, xanthurenic acid, and pantothenate; a lipid panel of LPA 18:0, DAG 16:0/18:0, LPA 16:0, and DAG 18:1/18:1; or a combination of these panels. |
| priorityDate | 2017-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.